-
公开(公告)号：US20060182771A1
公开(公告)日：2006-08-17
申请号：US11351844
申请日：2006-02-09
IPC分类号： A61K31/4745 , A61K9/00
CPC分类号： A61K9/0046 , A61K9/0019 , A61K9/0048 , A61K31/045 , A61K31/436 , A61K31/44 , A61K31/4745 , A61K47/10 , A61K47/12 , A61K47/44
摘要： Diseases and conditions associated with tissues of the body, including tissues in the eye, can be effectively treated by administering therapeutic agents to those tissues. Described herein are self-emulsifying formulations and methods for delivering therapeutic agents to such tissues. A self-emulsifying formulation may be delivered to an aqueous medium of a subject, including but not limited to the vitreous. A method may, for instance, be used to administer rapamycin or related compounds to treat or prevent choroidal neovascularization associated with age-related macular degeneration, or to treat dry AMD. A self-emulsifying formulation may also be administered systemically, such as orally, to treat transplant rejection in a subject. A self-emulsifying formulation may comprise rapamycin, related compounds, or other therapeutic agents.
摘要翻译： 可以通过向这些组织施用治疗剂来有效地治疗与身体组织（包括眼睛中的组织）相关的疾病和病症。 本文描述了将治疗剂递送到这种组织的自乳化制剂和方法。 自乳化制剂可以递送到受试者的水性介质，包括但不限于玻璃体。 例如，可以使用方法来施用雷帕霉素或相关化合物以治疗或预防与年龄相关性黄斑变性相关的脉络膜新血管形成，或治疗干性AMD。 自乳化制剂也可以全身施用，例如口服给药以治疗受试者的移植排斥。 自乳化制剂可以包含雷帕霉素，相关化合物或其它治疗剂。
-
公开(公告)号：US20060264453A1
公开(公告)日：2006-11-23
申请号：US11352092
申请日：2006-02-09
IPC分类号： A61K31/4745 , A61K31/045
CPC分类号： A61K9/0046 , A61K9/0019 , A61K9/0048 , A61K31/045 , A61K31/436 , A61K31/44 , A61K31/4745 , A61K47/10 , A61K47/12 , A61K47/44
摘要： Described herein are liquid rapamycin formulations. Described herein are methods of treating or preventing diseases or conditions, such as choroidal neovascularization, wet AMD and dry AMD, and preventing transition of dry AMD to wet AMD, using the liquid rapamycin formulations described herein.
摘要翻译： 本文描述的是液体雷帕霉素制剂。 本文描述了使用本文所述的液体雷帕霉素制剂治疗或预防疾病或病症如脉络膜新生血管形成，湿性AMD和干性AMD的方法，以及防止干性AMD转变为湿性AMD。
-
公开(公告)号：US08492400B2
公开(公告)日：2013-07-23
申请号：US11704442
申请日：2007-02-09
IPC分类号： A61K31/445
CPC分类号： A61K31/436 , A61K31/445 , A61K31/4745 , A61K33/00 , A61K45/06 , B01F13/02
摘要： Described herein are formulations comprising therapeutic agents, including but not limited to formulations comprising rapamycin, pharmaceutical formulations, unit dose forms, kits, methods of preparing formulations, and methods of using formulations. Such formulations and methods have increased stability.
摘要翻译： 本文描述的是包含治疗剂的制剂，包括但不限于包含雷帕霉素的制剂，药物制剂，单位剂量形式，试剂盒，制剂的制备方法和使用制剂的方法。 这些制剂和方法具有增加的稳定性。
-
公开(公告)号：US20100227879A1
公开(公告)日：2010-09-09
申请号：US12778872
申请日：2010-05-12
IPC分类号： A61K31/436 , A61P27/02
CPC分类号： A61K9/0046 , A61K9/0019 , A61K9/0048 , A61K31/045 , A61K31/436 , A61K31/44 , A61K31/4745 , A61K47/10 , A61K47/12 , A61K47/44
摘要： Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; non-dispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration, or wet age-related macular degeneration in a subject. The liquid formulations may comprise rapamycin or other therapeutic agents.
摘要翻译： 包括但不限于眼睛中的组织的疾病和病症可被有效治疗，预防，抑制，发作延迟或由给予这些组织的治疗剂引起的回归。 本文描述的是液体制剂，其将多种治疗剂（包括但不限于雷帕霉素）递送给受试者较长时间; 当被置于受试者的水性介质中时形成非分散物质的液体制剂; 在水性介质中形成凝胶或凝胶状物质的非分散质量形成液体制剂; 液体制剂，包含治疗剂和多种聚合物; 以及使用液体制剂将治疗剂递送给受试者较长时间的方法。 液体制剂可以放置在受试者的水性介质中，包括但不限于通过眼内或眼周内施用，或靠近受试者待治疗的疾病或病症的位置放置。 可以使用方法来施用雷帕霉素以治疗或预防受试者的血管生成，脉络膜新生血管形成或年龄相关性黄斑变性或湿性年龄相关性黄斑变性。 液体制剂可以包含雷帕霉素或其它治疗剂。
-
公开(公告)号：US20060258698A1
公开(公告)日：2006-11-16
申请号：US11351761
申请日：2006-02-09
IPC分类号： A61K31/4745
CPC分类号： A61K9/0046 , A61K9/0019 , A61K9/0048 , A61K31/045 , A61K31/436 , A61K31/44 , A61K31/4745 , A61K47/10 , A61K47/12 , A61K47/44
摘要： Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; non-dispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration, or wet age-related macular degeneration in a subject. The liquid formulations may comprise rapamycin or other therapeutic agents.
-
公开(公告)号：US20060257450A1
公开(公告)日：2006-11-16
申请号：US11386290
申请日：2006-03-21
IPC分类号： A61K31/4745 , A61F2/02
CPC分类号： A61K9/0051 , A61K31/436 , A61K31/4745
摘要： Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are solid drug delivery systems and methods for providing extended delivery of therapeutic agents to such tissues. A solid drug delivery system may be placed in a subject, including but not limited to placement between the sclera and the conjunctiva or transscleral placement. Described methods may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, age-related macular degeneration, or wet age-related macular degeneration in a subject. The solid drug delivery devices may comprise rapamycin or other therapeutic agents. Also described are methods of treating ocular diseases or disorders by administering an antiproliferative agent, including but not limited to rapamycin, proximal to an ocular device.
摘要翻译： 包括但不限于眼睛中的组织的疾病和病症可被有效治疗，预防，抑制，发作延迟或由给予这些组织的治疗剂引起的回归。 本文描述的是用于向这些组织提供治疗剂的延长递送的固体药物递送系统和方法。 固体药物递送系统可以放置在受试者中，包括但不限于在巩膜和结膜之间的放置或经巩膜放置。 描述的方法可用于施用雷帕霉素以治疗或预防受试者的血管生成，脉络膜新生血管形成，年龄相关性黄斑变性或湿性年龄相关性黄斑变性。 固体药物递送装置可以包含雷帕霉素或其它治疗剂。 还描述了通过在近视眼装置上施用抗增生剂（包括但不限于雷帕霉素）来治疗眼部疾病或病症的方法。
-
公开(公告)号：US20050064010A1
公开(公告)日：2005-03-24
申请号：US10945682
申请日：2004-09-20
IPC分类号： A61K9/00 , A61K31/436 , A61K31/4745
CPC分类号： A61K9/0048 , A61K9/0019 , A61K31/436
摘要： Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or within the sclera and implanting solid structures containing the therapeutic agent adjacent to or within the sclera. These methods may be used for administering rapamycin or related compounds to treat choroidal neovascularization associated with age-related macular degeneration.
摘要翻译： 通过将这些组织交叉施用治疗剂，可以有效地治疗与眼后段组织相关的疾病。 用于递送治疗剂使得它们穿过巩膜并到达这些组织的组合物，装置和方法包括在巩膜附近或在巩膜附近注射溶液或悬浮液，并植入包含与巩膜内或巩膜内的治疗剂的固体结构。 这些方法可用于施用雷帕霉素或相关化合物以治疗与年龄相关的黄斑变性相关的脉络膜新生血管形成。
-
公开(公告)号：US20090074786A1
公开(公告)日：2009-03-19
申请号：US12193686
申请日：2008-08-18
申请人： Philippe J.M. Dor , Sreenivasu Mudumba , Thierry Nivaggioli , David A. Weber , Sidiq Farooq , Sudeep K. Takhar
发明人： Philippe J.M. Dor , Sreenivasu Mudumba , Thierry Nivaggioli , David A. Weber , Sidiq Farooq , Sudeep K. Takhar
IPC分类号： A61K31/436 , A61P27/02 , A61K39/395
CPC分类号： A61K31/436
摘要： Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; non-dispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration, or wet age-related macular degeneration in a subject. The liquid formulations may comprise rapamycin or other therapeutic agents.
摘要翻译： 包括但不限于眼睛中的组织的疾病和病症可被有效治疗，预防，抑制，发作延迟或由给予这些组织的治疗剂引起的回归。 本文描述的是液体制剂，其将多种治疗剂（包括但不限于雷帕霉素）递送给受试者较长时间; 当被置于受试者的水性介质中时形成非分散物质的液体制剂; 在水性介质中形成凝胶或凝胶状物质的非分散质量形成液体制剂; 液体制剂，包含治疗剂和多种聚合物; 以及使用液体制剂将治疗剂递送给受试者较长时间的方法。 液体制剂可以放置在受试者的水性介质中，包括但不限于通过眼内或眼周内施用，或靠近受试者待治疗的疾病或病症的位置放置。 可以使用方法来施用雷帕霉素以治疗或预防受试者的血管生成，脉络膜新生血管形成或年龄相关性黄斑变性或湿性年龄相关性黄斑变性。 液体制剂可以包含雷帕霉素或其它治疗剂。
-
公开(公告)号：US20070203173A1
公开(公告)日：2007-08-30
申请号：US11704442
申请日：2007-02-09
IPC分类号： A61K31/4745
CPC分类号： A61K31/436 , A61K31/445 , A61K31/4745 , A61K33/00 , A61K45/06 , B01F13/02
摘要： Described herein are formulations comprising therapeutic agents, including but not limited to formulations comprising rapamycin, pharmaceutical formulations, unit dose forms, kits, methods of preparing formulations, and methods of using formulations. Such formulations and methods have increased stability.
摘要翻译： 本文描述的是包含治疗剂的制剂，包括但不限于包含雷帕霉素的制剂，药物制剂，单位剂量形式，试剂盒，制剂的制备方法和使用制剂的方法。 这些制剂和方法具有增加的稳定性。
-
20.发明授权公开(公告)号：US07976867B2
公开(公告)日：2011-07-12
申请号：US10735318
申请日：2003-12-12
申请人： Charles E. Lundy , Gary Wynn Cleary , Adrian Louis Faasse , Michael George Marcoux , Sreenivasu Mudumba
发明人： Charles E. Lundy , Gary Wynn Cleary , Adrian Louis Faasse , Michael George Marcoux , Sreenivasu Mudumba
CPC分类号： A61K9/703 , A61K9/7084 , A61K31/60
摘要： A dermal, transdermal, mucosal or transmucosal delivery device is provided. The device includes a backing layer, defining an ingredient containing reservoir, a cover for the reservoir having at least one opening therethrough, an adhesive layer and a liner layer. Upon removal of the liner layer, the device may be placed over the desired area of the skin or mucosa and adhesively applied thereto allowing the ingredients to flow from the reservoir through the at least one opening to the dermis or mucosa.
摘要翻译： 提供了皮肤，透皮，粘膜或经粘膜递送装置。 该装置包括背衬层，限定含有成分的储存器，用于储存器的盖具有穿过其中的至少一个开口，粘合剂层和衬垫层。 在去除衬里层时，可以将装置放置在皮肤或粘膜的期望区域上并粘附施加于其上，从而允许成分从储存器流过至少一个开口至真皮或粘膜。
-
-
-
-
-
-
-
-
-
搜索结果
21 条记录 (耗时 0.038 秒)
